MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Exact Sciences Corporation Revenue 2011-2026 | EXAS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Exact Sciences Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.76 B | 2.5 B | 2.08 B | 1.77 B | 1.49 B | 876 M | 454 M | 266 M | 99.4 M | 39.4 M | 1.8 M | 4.14 M | 4.14 M | 4.16 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.76 B | 1.8 M | 882 M |
Quarterly Revenue Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 851 M | 811 M | 707 M | - | 709 M | 699 M | 638 M | - | 628 M | 622 M | 602 M | - | 523 M | 522 M | 487 M | 474 M | 456 M | 435 M | 402 M | 466 M | 408 M | 269 M | 348 M | 296 M | 219 M | 200 M | 162 M | 143 M | 118 M | 103 M | 90.3 M | 87.4 M | 72.6 M | 57.6 M | 48.4 M | - | - | - | - | - | 12.6 M | 8.12 M | 4.27 M | - | 294 K | 294 K | 294 K | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 851 M | 294 K | 254 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
41 M | - | - | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 29.8 | -3.87 % | $ 321 M |  China |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | - | - | $ 79.8 M | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.13 | -3.54 % | $ 1.44 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | - | - | $ 914 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Danaher Corporation
DHR
|
23.9 B | $ 219.93 | 0.09 % | $ 161 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
3.62 B | - | - | $ 26.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.87 B | $ 209.75 | 2.09 % | $ 23.3 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
280 M | $ 19.51 | -5.18 % | $ 1.05 B | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 11.07 | 1.37 % | $ 314 M | Israel |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
46.9 M | $ 1.82 | - | $ 7.98 M | USA |
 |
Lantheus Holdings
LNTH
|
1.53 B | $ 67.04 | - | $ 4.64 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 23.02 | - | $ 696 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | - | -0.62 % | $ 28.7 B |  Schweiz |
 |
Guardant Health
GH
|
739 M | $ 106.6 | 1.65 % | $ 13.1 B | USA |
 |
NeoGenomics
NEO
|
661 M | $ 11.47 | - | $ 1.45 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Natera
NTRA
|
820 M | - | -0.5 % | $ 20.7 B | USA |
 |
OPKO Health
OPK
|
184 M | $ 1.25 | 2.05 % | $ 868 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
4.05 B | - | -9.16 % | $ 8.49 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
18 B | $ 32.03 | -2.72 % | $ 20 B | Niderland |
 |
IDEXX Laboratories
IDXX
|
3.9 B | - | - | $ 53.5 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 117.01 | -1.95 % | $ 18.6 B | USA |
 |
IQVIA Holdings
IQV
|
15.4 B | $ 176.27 | - | $ 32 B | USA |
|
Biodesix
BDSX
|
71.3 M | - | - | $ 1.33 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
13 B | $ 289.4 | 1.75 % | $ 24.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 3.56 | -4.56 % | $ 1.91 M | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | - | - | $ 11 B |  Irlanda |
 |
Quidel Corporation
QDEL
|
1.66 B | - | -3.13 % | $ 1.19 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.23 | - | $ 5.12 M | USA |
 |
Bioventus
BVS
|
512 M | $ 8.04 | - | $ 504 M | USA |